No influence of V617F mutation in JAK2 on outcome after allogeneic hematopoietic stem cell transplantation (HSCT) for myelofibrosis

被引：17

作者：

Ditschkowski, Markus ^{[1
]}

Elmaagacli, Ahmet H. ^{[1
]}

Trenschel, Rudolf ^{[1
]}

Steckel, Nina K. ^{[1
]}

Koldehoff, Michael ^{[1
]}

Beelen, Dietrich W. ^{[1
]}

机构：

[1] Univ Hosp Essen, Dept Bone Marrow Transplantat, Essen, Germany

来源：

BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION | 2006年 / 12卷 / 12期

关键词：

D O I：

10.1016/j.bbmt.2006.07.010

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：1350 / 1351

页数：2

共 8 条

[1] Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders [J].

Baxter, EJ ;

Scott, LM ;

Campbell, PJ ;

East, C ;

Fourouclas, N ;

Swanton, S ;

Vassiliou, GS ;

Bench, AJ ;

Boyd, EM ;

Curtin, N ;

Scott, MA ;

Erber, WN ;

Green, AR .

LANCET, 2005, 365 (9464) :1054-1061

[2] V617F mutation in JAK2 is associated idiopathic myelofibrosis [J].

Campbell, PJ ;

Griesshammer, M ;

Döhner, K ;

Döhner, H ;

Kusec, R ;

Hasselbalch, HC ;

Larsen, TS ;

Pallisgaard, N ;

Giraudier, S ;

Le Bousse-Kerdilès, MC ;

Desterke, C ;

Guerton, B ;

Dupriez, B ;

Bordessoule, D ;

Fenaux, P ;

Kiladjian, JJ ;

Viallard, JF ;

Brière, J ;

Harrison, CN ;

Green, AR ;

Reilly, JT .

BLOOD, 2006, 107 (05) :2098-2100

[3] Outcome of allogeneic stem cell transplantation in patients with myelofibrosis [J].

Ditschkowski, M ;

Beelen, DW ;

Trenschel, R ;

Koldehoff, M ;

Elmaagacli, AH .

BONE MARROW TRANSPLANTATION, 2004, 34 (09) :807-813

[4]

Guardiola P, 1999, BLOOD, V93, P2831

[5] A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera [J].

James, C ;

Ugo, V ;

Le Couédic, JP ;

Staerk, J ;

Delhommeau, F ;

Lacout, C ;

Garçon, L ;

Raslova, H ;

Berger, R ;

Bennaceur-Griscelli, A ;

Villeval, JL ;

Constantinescu, SN ;

Casadevall, N ;

Vainchenker, W .

NATURE, 2005, 434 (7037) :1144-1148

[6] Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders [J].

Jones, AV ;

Kreil, S ;

Zoi, K ;

Waghorn, K ;

Curtis, C ;

Zhang, LY ;

Score, J ;

Seear, R ;

Chase, AJ ;

Grand, FH ;

White, H ;

Zoi, C ;

Loukopoulos, D ;

Terpos, E ;

Vervessou, EC ;

Schultheis, B ;

Emig, M ;

Ernst, T ;

Lengfelder, E ;

Hehlmann, R ;

Hochhaus, A ;

Oscier, D ;

Silver, RT ;

Reiter, A ;

Cross, NCP .

BLOOD, 2005, 106 (06) :2162-2168

[7] A gain-of-function mutation of JAK2 in myeloproliferative disorders [J].

Kralovics, R ;

Passamonti, F ;

Buser, AS ;

Teo, S ;

Tiedt, R ;

Passweg, JR ;

Tichelli, A ;

Cazzola, M ;

Skoda, RC .

NEW ENGLAND JOURNAL OF MEDICINE, 2005, 352 (17) :1779-1790

[8] Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis [J].

Levine, RL ;

Wadleigh, M ;

Cools, J ;

Ebert, BL ;

Wernig, G ;

Huntly, BJP ;

Boggon, TJ ;

Wlodarska, L ;

Clark, JJ ;

Moore, S ;

Adelsperger, J ;

Koo, S ;

Lee, JC ;

Gabriel, S ;

Mercher, T ;

D'Andrea, A ;

Fröhling, S ;

Döhner, K ;

Marynen, P ;

Vandenberghe, P ;

Mesa, RA ;

Tefferi, A ;

Griffin, JD ;

Eck, MJ ;

Sellers, WR ;

Meyerson, M ;

Golub, TR ;

Lee, SJ ;

Gilliland, DG .

CANCER CELL, 2005, 7 (04) :387-397

← 1 →